Bernard is a Managing Director in Healthcare Investment Banking at Canaccord Genuity (Australia). He has advised senior management teams and boards for over 15 years on a range of financial and strategic matters, successfully executing over 100 transactions, including US$10 billion in financings and US$80 billion in M&A and advisory activities. Bernard returned to Australia after spending 17 years in New York, US. Prior to joining the Australian team in 2023, Bernard was a Managing Director in Healthcare Investment Banking at Canaccord Genuity (US) for over 5 years and an Executive Director in Healthcare Investment Banking at Oppenheimer & Co (US) for over 7 years. Bernard has a PhD from the University of Adelaide and an MBA from Stern School of Business at New York University.
Selected Transactions
-
A$100m
Immutep
Joint Lead Manager (JUMBO)
-
Sigilon Therapeutics
Financial Advisor (Sell side)
-
A$20m
ImpediMed
Joint Lead Manager (Placement)
-
US$20m
Vyant Bio
Sole Agent (ATM Offering)
-
US$50m
Clene
Lead Agent (ATM Offering)
-
US$296m
ImmunoGen Inc.
Lead Manager (Follow-On Offering)
-
$135m
ObsEva
Committed debt facility
-
US$100m
Oramed
Sole Agent (ATM Offering)
-
US$28m
Oramed
Sole Agent (ATM Offering)